Liquidia Corporation $LQDA Shares Sold by Mirabella Financial Services LLP

Mirabella Financial Services LLP decreased its holdings in shares of Liquidia Corporation (NASDAQ:LQDA) by 45.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 247,405 shares of the company’s stock after selling 203,827 shares during the quarter. Mirabella Financial Services LLP’s holdings in Liquidia were worth $5,626,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Federated Hermes Inc. acquired a new stake in Liquidia during the third quarter worth approximately $7,290,000. Caprock Group LLC purchased a new position in shares of Liquidia in the 3rd quarter valued at $37,114,000. Apis Capital Advisors LLC purchased a new position in shares of Liquidia in the 3rd quarter valued at $9,569,000. Farallon Capital Management LLC raised its stake in Liquidia by 102.1% during the 3rd quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock worth $194,783,000 after acquiring an additional 4,326,876 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC acquired a new stake in Liquidia during the 3rd quarter worth $2,026,000. 64.54% of the stock is owned by institutional investors and hedge funds.

Liquidia Price Performance

Shares of LQDA opened at $36.63 on Thursday. The company has a current ratio of 2.01, a quick ratio of 1.84 and a debt-to-equity ratio of 2.97. The stock’s 50 day moving average is $37.77 and its two-hundred day moving average is $31.47. Liquidia Corporation has a twelve month low of $11.26 and a twelve month high of $46.67. The firm has a market capitalization of $3.23 billion, a PE ratio of -44.13 and a beta of 0.52.

Liquidia (NASDAQ:LQDA) last issued its earnings results on Thursday, March 5th. The company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.08 by $0.07. The business had revenue of $92.02 million during the quarter, compared to the consensus estimate of $87.49 million. Liquidia had a negative return on equity of 209.33% and a negative net margin of 43.53%.Liquidia’s revenue for the quarter was up 3072.4% on a year-over-year basis. Research analysts anticipate that Liquidia Corporation will post -1.51 earnings per share for the current year.

Insider Activity

In other Liquidia news, insider Scott Moomaw sold 20,533 shares of the firm’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $37.43, for a total value of $768,550.19. Following the completion of the sale, the insider owned 154,514 shares of the company’s stock, valued at approximately $5,783,459.02. This trade represents a 11.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Russell Schundler sold 27,289 shares of the business’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $37.43, for a total transaction of $1,021,427.27. Following the sale, the general counsel owned 579,394 shares in the company, valued at $21,686,717.42. The trade was a 4.50% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 212,534 shares of company stock valued at $7,964,719 over the last three months. 26.50% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. BTIG Research boosted their target price on Liquidia from $49.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, March 5th. HC Wainwright boosted their target price on Liquidia from $50.00 to $55.00 and gave the company a “buy” rating in a report on Friday, March 6th. Zacks Research downgraded Liquidia from a “strong-buy” rating to a “hold” rating in a report on Friday, February 27th. Oppenheimer lifted their price objective on shares of Liquidia from $16.00 to $19.00 and gave the company an “underperform” rating in a research report on Thursday, March 12th. Finally, Wall Street Zen raised shares of Liquidia from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Liquidia currently has an average rating of “Moderate Buy” and an average target price of $42.67.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).